Clinical trial
Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer
NCT00106262 · Women and Infants Hospital of Rhode Island, Other · Terminated
Key facts
| NCT number | NCT00106262 |
|---|---|
| Title | Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer |
| Official title | A Phase II Study of VELCADE TM(PS-341) and Irinotecan in the Treatment of Progressive, Recurrent or Metastatic Cervical, Vulvar, or Vaginal Cancer |
| Lead sponsor | Women and Infants Hospital of Rhode Island, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | Velcade (bortezomib), Irinotecan |
| Enrollment | 38 |
| Start date | Mar 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Mar 22, 2005 |
| Last update posted | Apr 18, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: